Compares two robotic surgery systems for prostate and kidney cancer operations
Compares the HUGO RAS and da Vinci robots in adults with prostate or kidney cancer.
Plain-language title generated from the registry record
Registry title: Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
Key facts
- Where
- Bologna, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with prostate cancer or kidney cancer who will have robot-assisted surgery: radical prostatectomy or partial nephrectomy.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Prostate cancer: clinical stage cT1-T3b, N0-1. Kidney cancer: cancer confined to the kidney, clinical stage T1a or T1b.
Main reasons for not taking part
- Metastatic prostate cancer (M1)
- Metastatic kidney cancer (M1)
- Prefers another radical treatment instead of surgery, such as external radiotherapy (prostate cancer)
- Needs radical nephrectomy (kidney cancer)
- Other conditions the health care team considers a reason not to join
Read by machine on 12 November 2026.
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Eugenio BrunocillaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06844513
- Record updated
- 25 February 2025
- Original description
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).Read full original descriptionShow less
HUGO RAS Robotic Platform for Radical Prostatectomy and Partial Nephrectomy: Comparison with the Da Vinci Robotic Platform
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).
Inclusion: Patients with Prostate Cancer (Group A); Age ≥ 18 years; Life expectancy greater than 10 years; Diagnosis of prostate cancer following prostate needle biopsy; Clinical stage cT1-T3b, N0-1 disease; Positive anesthetic fitness assessment for robot-assisted radical prostatectomy; Provision of informed consent for the study; Patients with Kidney Cancer (Group B); Age ≥ 18 years; Radiological diagnosis of organ-confined kidney cancer at clinical stage T1a or T1b; Underwent CT and/or MRI of the abdomen with contrast medium; Positive anesthetic fitness assessment for robot-assisted partial nephrectomy; Provision of informed consent for the study.
Exclusion: Expression of a preference for radical treatment other than surgery (e.g., external radiotherapy); Patients with Prostate Cancer (Group A); Metastatic prostate cancer (M1); Other conditions deemed by healthcare professionals to contraindicate inclusion in the study; Patients with Kidney Cancer (Group B); Metastatic kidney cancer (M1); Other conditions deemed by healthcare professionals to contraindicate inclusion in the study; Indication for radical nephrectomy.